{
  "model": "gpt-5.2",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "result": {
    "text": "- [x] Wrote `output/study_overview.json`\n- [x] Wrote `output/quantitative_findings.json`\n- [x] Wrote `output/claim_audit.json`\n- [x] Wrote `output/public_summary.json`",
    "thoughts": "",
    "steps": [
      {
        "step": 1,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0c00244c92ca112100698de4ec469c819192cc435b9a39e8e2\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"TASK.md\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_TSPt9Nc6wAqiOMyX1mgsn95o\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent facts or numbers absent from the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - For claim evidence quotes, copy exact report snippets.\nL25: - Use relative paths only.\nL26: - Never use absolute paths.\nL27: - Never use `..` in paths.\nL28: - Write valid JSON only.\nL29: \nL30: ## Completion\nL31: Respond with a checklist of written output files.",
            "callId": "call_TSPt9Nc6wAqiOMyX1mgsn95o"
          }
        ],
        "usage": {
          "promptTokens": 487,
          "cachedTokens": 0,
          "responseTokens": 31,
          "thinkingTokens": 18,
          "totalTokens": 536
        },
        "costUsd": 0.0015382500000000001
      },
      {
        "step": 2,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0c00244c92ca112100698de4efbed081919874ea09aa8b79f3\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"dir_path\\\":\\\"schemas\\\",\\\"ignore\\\":null,\\\"file_filtering_options\\\":{\\\"respect_git_ignore\\\":true,\\\"respect_gemini_ignore\\\":true}}\",\n  \"call_id\": \"call_ANxUDJ0hqlzpPbhMYdsTQ6oi\",\n  \"name\": \"list_directory\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "schemas",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": true,
                "respect_gemini_ignore": true
              }
            },
            "output": "claim_audit.schema.json\npublic_summary.schema.json\nquantitative_findings.schema.json\nstudy_overview.schema.json",
            "callId": "call_ANxUDJ0hqlzpPbhMYdsTQ6oi"
          }
        ],
        "usage": {
          "promptTokens": 914,
          "cachedTokens": 0,
          "responseTokens": 44,
          "thinkingTokens": 28,
          "totalTokens": 986
        },
        "costUsd": 0.0026075
      },
      {
        "step": 3,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0c00244c92ca112100698de4f34e1c819183c073847c097f2f\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/study_overview.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_CBaHpNHXX6XPJX8uet11dDyR\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0c00244c92ca112100698de4f34e30819185e8179eea73e5c6\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/quantitative_findings.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_MYQhOrC2odlHNRCfdQ85bQfM\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0c00244c92ca112100698de4f34e3c8191877ea92a9a50bd9c\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/claim_audit.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_4Q8gieIdbpUnifFx99rd1ZQv\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0c00244c92ca112100698de4f34e488191b5cddddfbe005013\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/public_summary.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_CCtnoBg7oD5OZFxsjaY5H6ak\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }",
            "callId": "call_CBaHpNHXX6XPJX8uet11dDyR"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }",
            "callId": "call_MYQhOrC2odlHNRCfdQ85bQfM"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }",
            "callId": "call_4Q8gieIdbpUnifFx99rd1ZQv"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }",
            "callId": "call_CCtnoBg7oD5OZFxsjaY5H6ak"
          }
        ],
        "usage": {
          "promptTokens": 1020,
          "cachedTokens": 0,
          "responseTokens": 139,
          "thinkingTokens": 0,
          "totalTokens": 1159
        },
        "costUsd": 0.003731
      },
      {
        "step": 4,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0c00244c92ca112100698de4f64e108191a0a0de2de2b69e8a\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"input/report.md\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_vR0BtHxXMPD7ezVUBOQ2rYAi\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "call_vR0BtHxXMPD7ezVUBOQ2rYAi"
          }
        ],
        "usage": {
          "promptTokens": 4116,
          "cachedTokens": 0,
          "responseTokens": 32,
          "thinkingTokens": 30,
          "totalTokens": 4178
        },
        "costUsd": 0.008071
      },
      {
        "step": 5,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0c00244c92ca112100698de5009c2481919febb0428348370a\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"dir_path\\\":\\\"output\\\",\\\"ignore\\\":null,\\\"file_filtering_options\\\":{\\\"respect_git_ignore\\\":true,\\\"respect_gemini_ignore\\\":true}}\",\n  \"call_id\": \"call_kBX3sD9xsrDyQlKrnad81Bln\",\n  \"name\": \"list_directory\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "output",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": true,
                "respect_gemini_ignore": true
              }
            },
            "output": "claim_audit.json\npublic_summary.json\nquantitative_findings.json\nstudy_overview.json",
            "callId": "call_kBX3sD9xsrDyQlKrnad81Bln"
          }
        ],
        "usage": {
          "promptTokens": 5253,
          "cachedTokens": 1024,
          "responseTokens": 44,
          "thinkingTokens": 481,
          "totalTokens": 5778
        },
        "costUsd": 0.01492995
      },
      {
        "step": 6,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0c00244c92ca112100698de504e35c81919bbf1a4c52c22e50\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/study_overview.json\\\",\\\"offset\\\":0,\\\"limit\\\":2000}\",\n  \"call_id\": \"call_S30zqL9Xz6u29aHTxLamFfKq\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0c00244c92ca112100698de504e3708191a504ad560e899048\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/quantitative_findings.json\\\",\\\"offset\\\":0,\\\"limit\\\":2000}\",\n  \"call_id\": \"call_tOgExq18SZMvqOhfQGXRr2jw\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0c00244c92ca112100698de504e3788191acf8861222ca6b7d\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/claim_audit.json\\\",\\\"offset\\\":0,\\\"limit\\\":2000}\",\n  \"call_id\": \"call_HgC5tlbskmA72LBniMpS5NXd\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0c00244c92ca112100698de504e3808191bd840b4467e1263e\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/public_summary.json\\\",\\\"offset\\\":0,\\\"limit\\\":2000}\",\n  \"call_id\": \"call_aqb8ZUyBeeWA3vcguS4WwFVB\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: {}",
            "callId": "call_S30zqL9Xz6u29aHTxLamFfKq"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: {}",
            "callId": "call_tOgExq18SZMvqOhfQGXRr2jw"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: {}",
            "callId": "call_HgC5tlbskmA72LBniMpS5NXd"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: {}",
            "callId": "call_aqb8ZUyBeeWA3vcguS4WwFVB"
          }
        ],
        "usage": {
          "promptTokens": 5808,
          "cachedTokens": 0,
          "responseTokens": 137,
          "thinkingTokens": 41,
          "totalTokens": 5986
        },
        "costUsd": 0.012655999999999999
      },
      {
        "step": 7,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_0c00244c92ca112100698de545b28c81918ffd531d725390cf\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/study_overview.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"paper\\\\\\\": {\\\\n    \\\\\\\"title\\\\\\\": \\\\\\\"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\\\\\\\",\\\\n    \\\\\\\"doi\\\\\\\": \\\\\\\"10.1038/s41586-025-09006-8\\\\\\\",\\\\n    \\\\\\\"publication_year\\\\\\\": 2025,\\\\n    \\\\\\\"domain\\\\\\\": \\\\\\\"oncology-immunology\\\\\\\",\\\\n    \\\\\\\"study_type\\\\\\\": \\\\\\\"preclinical+retrospective\\\\\\\"\\\\n  },\\\\n  \\\\\\\"core_question\\\\\\\": \\\\\\\"Whether intratumoral delivery of an mRNA vaccine can induce an interferon-rich inflammatory state that increases tumour sensitivity to anti-PD-L1 immune checkpoint blockade.\\\\\\\",\\\\n  \\\\\\\"datasets_or_cohorts\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"mouse-efficacy-combo\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Mouse efficacy cohort (combination therapy)\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"78 tumor-bearing mice pooled across repeat experiments\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Preclinical murine tumour models testing intratumoral mRNA vaccination in combination with anti-PD-L1 as an efficacy setting for tumour control and immune infiltration readouts.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"mouse-matched-controls\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Mouse control cohort (vaccine only, ICI only, vehicle)\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"84 tumor-bearing mice pooled across matched controls\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Matched preclinical control groups used to distinguish combination effects from vaccine-only, ICI-only, or vehicle outcomes, and to support interpretation of sensitization versus standalone activity.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"human-retrospective-metastatic\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Human retrospective metastatic cohort under ICI\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"130 patients total (43 vaccinated; 87 unvaccinated)\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Translational retrospective cohort of metastatic patients receiving immune checkpoint inhibitor treatment, compared by prior SARS-CoV-2 mRNA vaccination status to assess associations with survival outcomes.\\\\\\\"\\\\n    }\\\\n  ],\\\\n  \\\\\\\"major_limitations\\\\\\\": [\\\\n    \\\\\\\"Human analysis is retrospective and non-randomized; residual confounding is likely.\\\\\\\",\\\\n    \\\\\\\"Vaccination timing relative to ICI initiation varied across patients.\\\\\\\",\\\\n    \\\\\\\"Tumor-type mix and treatment-history heterogeneity limit causal interpretation.\\\\\\\",\\\\n    \\\\\\\"Mouse model effects may not map one-to-one to all human tumors.\\\\\\\",\\\\n    \\\\\\\"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\\\\\\\"\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_DGegOojG3o4tQVIW0mCWxWFf\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0c00244c92ca112100698de545b29c8191a66f4fdc8e824497\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/quantitative_findings.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"findings\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q01\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Fraction of tumor proteins represented in immunopeptidome\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"62.3%\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"37.3% (comparator)\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination was associated with a broader set of tumour proteins being represented in the immunopeptidome.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\n        \\\\\\\"L28\\\\\\\"\\\\n      ]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q02\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Fraction of proteins represented in MHC-I peptidome\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"40.6%\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"20.6% (comparator)\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"The MHC-I-presented peptide landscape expanded in the condition described for mRNA vaccination, consistent with increased antigen presentation.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\n        \\\\\\\"L29\\\\\\\"\\\\n      ]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q03\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Retrospective human survival comparison p-value\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"p=0.01\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"Not applicable (p-value reported for vaccinated vs unvaccinated comparison)\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"In the retrospective metastatic cohort receiving ICI treatment, prior SARS-CoV-2 mRNA vaccination status was associated with improved survival (reported p=0.01).\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\n        \\\\\\\"L30\\\\\\\"\\\\n      ]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q04\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Type I interferon response score (normalized units)\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"3.1\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0 (baseline/comparator)\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"Tumours showed a marked induction of a type I interferon response after intratumoral mRNA vaccination according to the normalized score reported.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\n        \\\\\\\"L31\\\\\\\"\\\\n      ]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q05\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"PD-L1 expression fold-change in tumor tissue\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"2.4x\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0x (baseline/comparator)\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"PD-L1 expression increased in tumour tissue, potentially increasing the relevance of targeting the PD-L1 axis with checkpoint blockade.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\n        \\\\\\\"L32\\\\\\\",\\\\n        \\\\\\\"L45\\\\\\\"\\\\n      ]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q06\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Intratumoral CD8+ T-cell density fold-change\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"1.8x\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0x (baseline/comparator)\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"The combination context reported increased CD8+ T-cell density in tumours, consistent with enhanced immune infiltration.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\n        \\\\\\\"L33\\\\\\\"\\\\n      ]\\\\n    }\\\\n  ],\\\\n  \\\\\\\"controls_or_null_results\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L36\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"ICI-only treatment had limited activity in low-immunogenic baseline settings.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L37\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L38\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L39\\\\\\\"\\\\n    }\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_lulpQ6BLQgIRhhblSISl6ueR\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0c00244c92ca112100698de545b2a48191addfc693f9bd5501\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/claim_audit.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"claims\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C01\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"Intratumoral delivery of an mRNA vaccine induces a type I interferon-rich inflammatory state in tumours.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L11\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L42\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L31\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"The report summarizes a mechanistic chain, but also notes that some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings (L53).\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C02\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"mRNA vaccination is associated with increased antigen processing/presentation and a broader MHC-I peptide repertoire in tumours.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Interferon-associated antigen processing and presentation pathways increase.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L43\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L44\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L29\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"Mouse model effects may not map one-to-one to all human tumors, and some mechanistic readouts varied across model systems (L52-L53).\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C03\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"In murine tumour models, combining intratumoral mRNA vaccination with anti-PD-L1 is described as improving tumour control and immune infiltration relative to baseline contexts.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"tentative\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"- Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L14\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L46\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L33\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"The report notes that vaccine-only and ICI-only conditions had limited or non-durable effects in some settings (L36-L37), and mouse model results may not translate directly to human tumours (L52).\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C04\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"In a retrospective metastatic patient cohort receiving ICI therapy, prior SARS-CoV-2 mRNA vaccination status was associated with improved survival.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"tentative\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L15\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L30\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Human retrospective metastatic cohort: 130 patients total.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L21\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"The human analysis is retrospective and non-randomized with likely residual confounding, and vaccination timing relative to ICI initiation varied across patients (L49-L50).\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C05\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"The sensitization effect depends on mRNA and type I interferon signaling, based on perturbation and control conditions described.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"- Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L16\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"- Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L38\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L39\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"The report frames these as controls/perturbations within preclinical settings; the extent to which the same dependency governs human outcomes is not established and mouse-to-human mapping is uncertain (L52).\\\\\\\"\\\\n    }\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_fJXGOuGVrym6SkqnGJKaRrfs\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_0c00244c92ca112100698de545b2ac8191ace1a632421088c0\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/public_summary.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"headline\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination may help tumours respond better to checkpoint blockade\\\\\\\",\\\\n  \\\\\\\"plain_language_summary\\\\\\\": \\\\\\\"Immune checkpoint inhibitors (ICIs) can work very well for some people with cancer, but many tumours do not respond because the immune system is not strongly activated against them. This study asks whether delivering an mRNA vaccine directly into a tumour can create a local, interferon-driven inflammatory state that makes the tumour more visible to immune cells and therefore more sensitive to anti-PD-L1 therapy (L11). In mouse tumour models, the authors report that intratumoral mRNA vaccination broadens the set of tumour proteins and peptides presented to the immune system (for example, 62.3% versus 37.3% of tumour proteins represented in an immunopeptidome comparison, and 40.6% versus 20.6% for the MHC-I peptidome; L28-L29). They also report increased markers linked to checkpoint biology and immune infiltration (for example, PD-L1 expression 2.4x and intratumoral CD8+ T-cell density 1.8x; L32-L33). In a separate, retrospective human cohort of metastatic patients treated with ICIs, prior SARS-CoV-2 mRNA vaccination was associated with improved survival (reported p=0.01; L30). However, because the human analysis was not randomized and vaccination timing and patient backgrounds varied, the results should be viewed as hypothesis-supporting rather than definitive proof of clinical benefit (L49-L52).\\\\\\\",\\\\n  \\\\\\\"what_is_new\\\\\\\": [\\\\n    \\\\\\\"The study links intratumoral mRNA vaccination to broader tumour antigen display on MHC-I, a potential mechanism for improved immune recognition (L28-L29, L44).\\\\\\\",\\\\n    \\\\\\\"It proposes a mechanistic chain where local type I interferon signaling drives antigen processing/presentation changes and increased PD-L1 pathway activity (L42-L45).\\\\\\\",\\\\n    \\\\\\\"It adds a retrospective human comparison suggesting vaccinated patients on ICI therapy had better survival (p=0.01), aligning with the preclinical hypothesis (L30, L46).\\\\\\\"\\\\n  ],\\\\n  \\\\\\\"why_caution_is_needed\\\\\\\": [\\\\n    \\\\\\\"The human findings come from a retrospective, non-randomized analysis where residual confounding is likely (L49).\\\\\\\",\\\\n    \\\\\\\"Vaccination timing relative to ICI initiation varied across patients, complicating interpretation of cause and effect (L50).\\\\\\\",\\\\n    \\\\\\\"Mouse model effects may not translate directly to all human tumours, and some mechanistic signals varied by model system (L52-L53).\\\\\\\",\\\\n    \\\\\\\"Control results indicate vaccine-only or ICI-only can be limited in some settings, so the benefit may depend on context and combination strategy (L36-L37).\\\\\\\"\\\\n  ],\\\\n  \\\\\\\"glossary\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"mRNA vaccine\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A vaccine that uses messenger RNA (mRNA) to instruct cells to make a protein that triggers immune activation; here it is delivered into tumours (L11, L42).\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Intratumoral\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"Given directly into a tumour, aiming to change the local tumour environment rather than relying only on whole-body exposure (L11, L14).\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Immune checkpoint inhibitor (ICI)\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A cancer therapy that blocks inhibitory immune pathways (checkpoints) to help T cells attack cancer; the report focuses on anti-PD-L1 (L11, L15).\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Type I interferon\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A family of immune signals that can drive inflammation and antiviral-like responses; the authors propose it helps reprogram tumours toward immune visibility (L42-L43).\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"MHC-I peptidome\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"The set of peptides displayed on MHC class I molecules, which can be recognized by CD8+ T cells and influences tumour detectability (L29, L44).\\\\\\\"\\\\n    }\\\\n  ],\\\\n  \\\\\\\"open_questions\\\\\\\": [\\\\n    \\\\\\\"Would a prospective randomized clinical trial confirm that prior or intratumoral mRNA vaccination improves outcomes with anti-PD-L1 therapy in people (L49, L56)?\\\\\\\",\\\\n    \\\\\\\"Which tumour types and baseline immune contexts are most likely to benefit, given limited activity of vaccine-only and ICI-only in some settings (L36-L37, L51)?\\\\\\\",\\\\n    \\\\\\\"How important are vaccination timing and dosing relative to ICI initiation for any clinical benefit (L50)?\\\\\\\",\\\\n    \\\\\\\"Can the same interferon-dependent mechanism observed in preclinical perturbations be demonstrated in human tumours (L39, L52)?\\\\\\\"\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_s052hJ0MKdGQXDGRFDZKL2oH\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Whether intratumoral delivery of an mRNA vaccine can induce an interferon-rich inflammatory state that increases tumour sensitivity to anti-PD-L1 immune checkpoint blockade.\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combo\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice pooled across repeat experiments\",\n      \"description\": \"Preclinical murine tumour models testing intratumoral mRNA vaccination in combination with anti-PD-L1 as an efficacy setting for tumour control and immune infiltration readouts.\"\n    },\n    {\n      \"id\": \"mouse-matched-controls\",\n      \"label\": \"Mouse control cohort (vaccine only, ICI only, vehicle)\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice pooled across matched controls\",\n      \"description\": \"Matched preclinical control groups used to distinguish combination effects from vaccine-only, ICI-only, or vehicle outcomes, and to support interpretation of sensitization versus standalone activity.\"\n    },\n    {\n      \"id\": \"human-retrospective-metastatic\",\n      \"label\": \"Human retrospective metastatic cohort under ICI\",\n      \"sample_size_or_observations\": \"130 patients total (43 vaccinated; 87 unvaccinated)\",\n      \"description\": \"Translational retrospective cohort of metastatic patients receiving immune checkpoint inhibitor treatment, compared by prior SARS-CoV-2 mRNA vaccination status to assess associations with survival outcomes.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"Human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "call_DGegOojG3o4tQVIW0mCWxWFf"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3% (comparator)\",\n      \"interpretation\": \"Intratumoral mRNA vaccination was associated with a broader set of tumour proteins being represented in the immunopeptidome.\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6% (comparator)\",\n      \"interpretation\": \"The MHC-I-presented peptide landscape expanded in the condition described for mRNA vaccination, consistent with increased antigen presentation.\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"Not applicable (p-value reported for vaccinated vs unvaccinated comparison)\",\n      \"interpretation\": \"In the retrospective metastatic cohort receiving ICI treatment, prior SARS-CoV-2 mRNA vaccination status was associated with improved survival (reported p=0.01).\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0 (baseline/comparator)\",\n      \"interpretation\": \"Tumours showed a marked induction of a type I interferon response after intratumoral mRNA vaccination according to the normalized score reported.\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x (baseline/comparator)\",\n      \"interpretation\": \"PD-L1 expression increased in tumour tissue, potentially increasing the relevance of targeting the PD-L1 axis with checkpoint blockade.\",\n      \"evidence_line_refs\": [\n        \"L32\",\n        \"L45\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x (baseline/comparator)\",\n      \"interpretation\": \"The combination context reported increased CD8+ T-cell density in tumours, consistent with enhanced immune infiltration.\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "call_lulpQ6BLQgIRhhblSISl6ueR"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral delivery of an mRNA vaccine induces a type I interferon-rich inflammatory state in tumours.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\",\n          \"line_ref\": \"L11\"\n        },\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\",\n          \"line_ref\": \"L31\"\n        }\n      ],\n      \"caveat\": \"The report summarizes a mechanistic chain, but also notes that some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings (L53).\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"mRNA vaccination is associated with increased antigen processing/presentation and a broader MHC-I peptide repertoire in tumours.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        },\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        },\n        {\n          \"quote\": \"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors, and some mechanistic readouts varied across model systems (L52-L53).\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"In murine tumour models, combining intratumoral mRNA vaccination with anti-PD-L1 is described as improving tumour control and immune infiltration relative to baseline contexts.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"- Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\n          \"line_ref\": \"L14\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"| Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\",\n          \"line_ref\": \"L33\"\n        }\n      ],\n      \"caveat\": \"The report notes that vaccine-only and ICI-only conditions had limited or non-durable effects in some settings (L36-L37), and mouse model results may not translate directly to human tumours (L52).\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"In a retrospective metastatic patient cohort receiving ICI therapy, prior SARS-CoV-2 mRNA vaccination status was associated with improved survival.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\",\n          \"line_ref\": \"L15\"\n        },\n        {\n          \"quote\": \"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"Human retrospective metastatic cohort: 130 patients total.\",\n          \"line_ref\": \"L21\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized with likely residual confounding, and vaccination timing relative to ICI initiation varied across patients (L49-L50).\"\n    },\n    {\n      \"claim_id\": \"C05\",\n      \"claim\": \"The sensitization effect depends on mRNA and type I interferon signaling, based on perturbation and control conditions described.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"- Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\",\n          \"line_ref\": \"L16\"\n        },\n        {\n          \"quote\": \"- Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n          \"line_ref\": \"L38\"\n        },\n        {\n          \"quote\": \"- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        }\n      ],\n      \"caveat\": \"The report frames these as controls/perturbations within preclinical settings; the extent to which the same dependency governs human outcomes is not established and mouse-to-human mapping is uncertain (L52).\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "call_fJXGOuGVrym6SkqnGJKaRrfs"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"Intratumoral mRNA vaccination may help tumours respond better to checkpoint blockade\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can work very well for some people with cancer, but many tumours do not respond because the immune system is not strongly activated against them. This study asks whether delivering an mRNA vaccine directly into a tumour can create a local, interferon-driven inflammatory state that makes the tumour more visible to immune cells and therefore more sensitive to anti-PD-L1 therapy (L11). In mouse tumour models, the authors report that intratumoral mRNA vaccination broadens the set of tumour proteins and peptides presented to the immune system (for example, 62.3% versus 37.3% of tumour proteins represented in an immunopeptidome comparison, and 40.6% versus 20.6% for the MHC-I peptidome; L28-L29). They also report increased markers linked to checkpoint biology and immune infiltration (for example, PD-L1 expression 2.4x and intratumoral CD8+ T-cell density 1.8x; L32-L33). In a separate, retrospective human cohort of metastatic patients treated with ICIs, prior SARS-CoV-2 mRNA vaccination was associated with improved survival (reported p=0.01; L30). However, because the human analysis was not randomized and vaccination timing and patient backgrounds varied, the results should be viewed as hypothesis-supporting rather than definitive proof of clinical benefit (L49-L52).\",\n  \"what_is_new\": [\n    \"The study links intratumoral mRNA vaccination to broader tumour antigen display on MHC-I, a potential mechanism for improved immune recognition (L28-L29, L44).\",\n    \"It proposes a mechanistic chain where local type I interferon signaling drives antigen processing/presentation changes and increased PD-L1 pathway activity (L42-L45).\",\n    \"It adds a retrospective human comparison suggesting vaccinated patients on ICI therapy had better survival (p=0.01), aligning with the preclinical hypothesis (L30, L46).\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human findings come from a retrospective, non-randomized analysis where residual confounding is likely (L49).\",\n    \"Vaccination timing relative to ICI initiation varied across patients, complicating interpretation of cause and effect (L50).\",\n    \"Mouse model effects may not translate directly to all human tumours, and some mechanistic signals varied by model system (L52-L53).\",\n    \"Control results indicate vaccine-only or ICI-only can be limited in some settings, so the benefit may depend on context and combination strategy (L36-L37).\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine that uses messenger RNA (mRNA) to instruct cells to make a protein that triggers immune activation; here it is delivered into tumours (L11, L42).\"\n    },\n    {\n      \"term\": \"Intratumoral\",\n      \"definition\": \"Given directly into a tumour, aiming to change the local tumour environment rather than relying only on whole-body exposure (L11, L14).\"\n    },\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A cancer therapy that blocks inhibitory immune pathways (checkpoints) to help T cells attack cancer; the report focuses on anti-PD-L1 (L11, L15).\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of immune signals that can drive inflammation and antiviral-like responses; the authors propose it helps reprogram tumours toward immune visibility (L42-L43).\"\n    },\n    {\n      \"term\": \"MHC-I peptidome\",\n      \"definition\": \"The set of peptides displayed on MHC class I molecules, which can be recognized by CD8+ T cells and influences tumour detectability (L29, L44).\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would a prospective randomized clinical trial confirm that prior or intratumoral mRNA vaccination improves outcomes with anti-PD-L1 therapy in people (L49, L56)?\",\n    \"Which tumour types and baseline immune contexts are most likely to benefit, given limited activity of vaccine-only and ICI-only in some settings (L36-L37, L51)?\",\n    \"How important are vaccination timing and dosing relative to ICI initiation for any clinical benefit (L50)?\",\n    \"Can the same interferon-dependent mechanism observed in preclinical perturbations be demonstrated in human tumours (L39, L52)?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_s052hJ0MKdGQXDGRFDZKL2oH"
          }
        ],
        "usage": {
          "promptTokens": 6040,
          "cachedTokens": 3968,
          "responseTokens": 3963,
          "thinkingTokens": 918,
          "totalTokens": 10921
        },
        "costUsd": 0.07265440000000001
      },
      {
        "step": 8,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "- [x] Wrote `output/study_overview.json`\n- [x] Wrote `output/quantitative_findings.json`\n- [x] Wrote `output/claim_audit.json`\n- [x] Wrote `output/public_summary.json`",
        "toolCalls": [],
        "usage": {
          "promptTokens": 10998,
          "cachedTokens": 10752,
          "responseTokens": 61,
          "thinkingTokens": 313,
          "totalTokens": 11372
        },
        "costUsd": 0.0075481
      }
    ],
    "totalCostUsd": 0.12373620000000002
  }
}
